Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00191074 | Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature | PHASE3 | COMPLETED | 11 | — | — | Feb 1, 2001 | Jan 1, 2006 | Mar 9, 2007 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| somatropin, rDNA origin, for injection | DRUG | - |
Inclusion Criteria: Participation in core, blinded phase and ability to be contacted by investigators. For patients who were on treatment at the time of amendment (g), growth velocity greater than or equal to 1.5 cm/year measured over the prior 12-month period. For patients who had chosen to disco...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Somapacitan, Norditropin FlexPro |
| Ascendis Pharma A/S | ASND | 1 | PHASE3 | Lonapegsomatropin, Somatropin Pen Injector |
| Harvard Bioscience, Inc. | HBIO | 1 | NA | Undisclosed |